Develops and commercializes novel treatments for B-cell malignancies. Focuses on therapies for autoimmune diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 210% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 18.4× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 41% of them.
Analysts' average target sits 49% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
The net profit margin is 73% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 210% a year on average.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 27/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 41/100.
On our five-subject report card, TGTX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TGTX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Analysts’ average target sits above today’s price, yet the valuation grade (41/100) says the stock isn’t cheap.